Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Cancer: early-phase trial registry
146 of 430 indexed Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #12 of 28,707 conditions by registered trial count.
430 US clinical trials · 146 currently recruiting · #12 of 28,707 conditions by registered trial count
Lung Cancer: 430 US clinical trials tracked, 146 recruiting.
Lung Cancer is the subject of 430 registered US clinical trials on ClinicalTrials.gov, 146 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 181 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 36 of these trials.
Enrollment posture brief
Registry condition lung-cancer
OPEN 146 | RECR 34% | LATE 23 | EARLY 181 | RANK #12 | SPON 36
Volume-matched condition peers
Nearest open-share peer: Solid Tumors (34% recruiting · 127 trials)
Lung Cancer lists 146 open slots (34% of 430 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Cancer is recruiting below its size-band peers.
146 of 430 indexed trials (34%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lung Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 36 of 430 trials (8.4%). 179 distinct sponsors appear on at least one study for this condition label.
-
Typical Lung Cancer enrolment sits around 89 participants.
Median target enrolment is 89 among the 410 trials that report a genuine target (sentinel values excluded). 212 of those (51.7%) plan for fewer than 100 participants.
-
Lung Cancer research is mostly interventional.
321 interventional and 109 observational studies make up this index (74.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
430 total, page 4 of 9
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
Nucleix
NCT04968548
Improving Utilization of Lung Cancer Screening in Underserved PA Populations
American College of Radiology
NCT04806399
Multilevel Interventions to Increase Adherence to Lung Cancer Screening
Kaiser Permanente
NCT05747443
Female Asian Nonsmoker Screening Study
NYU Langone Health
NCT05164757
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
NCT05179824
Increasing Adherence to Lung Cancer Screening
Abramson Cancer Center at Penn Medicine
NCT05832008
Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.
University of Colorado, Denver
NCT04739696
Nashville Early Diagnosis Lung Cancer Project
Vanderbilt-Ingram Cancer Center
NCT01475500
Validation of a Multi-gene Test for Lung Cancer Risk
University of Toledo Health Science Campus
NCT01130285
Clinical Utility for Ion Endoluminal System
Intuitive Surgical
NCT03893539
Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)
M.D. Anderson Cancer Center
NCT04200534
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT04699188
A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine
University of Arkansas
NCT02597738
Clinician-Patient Communication in Lung Cancer Care
Memorial Sloan Kettering Cancer Center
NCT02732834
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
Ohio State University Comprehensive Cancer Center
NCT02259218
Implementation of a System-level Tobacco Treatment Intervention
Dana-Farber Cancer Institute
NCT02816697
Genetic Susceptibility to Lung Cancer in Never Smokers
Memorial Sloan Kettering Cancer Center
NCT00597636
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Arcus Biosciences
NCT04736173
A Study to Evaluate Routine Chest Tube Management After Minimally Invasive Lung Surgery
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT04913415
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
iTeos Belgium
NCT05060432
A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life
Complement Theory
NCT06397651
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
NCT00600496
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT04899908
Reminder Messages for Lung Cancer Screening
M.D. Anderson Cancer Center
NCT05952778
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Memorial Sloan Kettering Cancer Center
NCT02675829
INHERIT EGFR - Studying Germline EGFR Mutations
Dana-Farber Cancer Institute
NCT01754025
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
NCT02638090
Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT06530615
Using e-Nose Technology to Identify Early Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT04734145
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
NCT02414269
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen
NCT04354246
Safety of Lung Cryobiopsy in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT04548830
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Nasser Hanna
NCT04367311
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
Carevive Systems
NCT05587972
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
AstraZeneca
NCT06194448
Implementation Strategies for Monitoring Adherence in Real Time
Abramson Cancer Center at Penn Medicine
NCT04347161
Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting
M.D. Anderson Cancer Center
NCT00618553
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
NCT03693014
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Merck Sharp & Dohme
NCT06698042
UG3 Pilot Clinical Trial
University of Utah
NCT07073898
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT03999710
Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)
University of California, Irvine
NCT06225414
Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer
Dana-Farber Cancer Institute
NCT00264602
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
M.D. Anderson Cancer Center
NCT05704634
MPDL3280A With Chemoradiation for Lung Cancer
M.D. Anderson Cancer Center
NCT02525757
Prospective Evaluation of the Tool-in-lesion Technology of the Galaxy System in Routine Clinical Practice
Noah Medical
NCT06685133
Early Detection of Lung Cancer
Vanderbilt-Ingram Cancer Center
NCT03181256
Pilot Study of SGRT Alone vs. SGRT With Fiducials for Breath Hold SBRT tx of the Lung
Wake Forest University Health Sciences
NCT04060927
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
HUYABIO International
NCT05485974
Testing the Engaged Approach to Lung Cancer Screening
University of Colorado, Denver
NCT06327074
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 85 |
| Phase 2 | 96 |
| Phase 3 | 22 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Cancer page
430 registered trials, 146 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 146 Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Lung Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Cancer condition card totals 430 registered trials; most-linked intervention paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.